Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Inc reported a Schedule 13G filing showing Vanguard Capital Management beneficially owned 11,514,893 shares of Common Stock, representing 5.34% of the class as of 03/31/2026. The filer reports 1,872,762 shares of sole voting power and sole dispositive power over 11,514,893 shares.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in INSMED Inc. On April 16, 2026, he exercised options for 10,699 shares of Common Stock at exercise prices of $30.46 and $17.16 per share.
That same day he sold a total of 10,699 shares of Common Stock in open-market transactions at weighted average prices between $142.39 and $146.02 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions he directly held 301,185 shares, with an additional 233,924 shares held indirectly by a trust.
INSMED Inc officer William Lewis reported a proposed sale of 10,699 common shares, with an aggregate market value of $1,540,292 and an approximate sale date of April 16, 2026.
The past-three-month table lists seven earlier sales from January 20 through April 6, 2026, with share amounts and gross proceeds for each. The form records September 4, 2025 as the plan adoption or giving-of-instruction date in its Rule 10b5-1 field.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock. On April 6, 2026, he exercised stock options for a total of 10,699 shares at strike prices of $30.46 and $17.16 per share, then sold 10,699 shares in open-market transactions at weighted average prices around $161.73, $163.23, and $164.01. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly owned about 301,185 shares of common stock, with an additional 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Insmed Incorporated reported that its Phase 2b CEDAR trial of brensocatib in moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints, and the company will discontinue development of brensocatib for HS.
The randomized, double-blind, placebo-controlled study enrolled 214 patients across 72 global sites. At Week 16, abscess and inflammatory nodule counts fell 45.5% and 40.3% in the 10 mg and 40 mg brensocatib arms, compared with a 57.1% reduction on placebo, indicating no efficacy advantage. Safety was consistent with prior studies, with similar rates of treatment-emergent adverse events and no new safety signals at either dose.
INSMED Inc officer William Lewis gave notice of a proposed sale of 10,699 common shares, with an aggregate market value of $1,746,319 and an approximate sale date of April 6, 2026. September 4, 2025 is identified as the plan-adoption or instruction date if relying on Rule 10b5-1. Lewis also sold 19,215 common shares on January 12, 2026, for gross proceeds of $3,247,325.
Insmed Inc Chief Operating Officer Roger Adsett exercised options to acquire 88,060 shares of common stock at an exercise price of $14.56 per share. On the same date, he sold 88,060 shares in open-market transactions at weighted average prices of $163.18, $164.11, and $164.95 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, he directly holds 106,810 shares of Insmed common stock.
INSMED Inc. officer Roger Adsett reported a proposed sale of 88,060 common shares, with an aggregate market value of $14,465,616 and an approximate sale date of April 1, 2026. The notice lists December 3, 2025 as the Rule 10b5-1 plan adoption or instruction date.
Insmed Incorporated is asking shareholders to vote at its virtual 2026 annual meeting on three items: electing two Class II directors, an advisory vote on 2025 executive pay, and ratifying Ernst & Young as auditor for 2026.
The company reports 2025 revenue of $606.4 million, driven by ARIKAYCE and the U.S. launch of BRINSUPRI, including a 19% year-over-year increase in global ARIKAYCE revenue and a stock price gain of over 150% in 2025. Insmed highlights a largely independent, skills-diverse Board, strong governance practices, and a pay program that is heavily equity-based and performance-linked, with about 94% of the CEO’s 2025 target direct compensation and 86% of other NEOs’ pay classified as “at risk.”